Core Viewpoint - Guangshentang's innovative drug GST-HG131 for hepatitis B treatment has received significant recognition from the American Association for the Study of Liver Diseases (AASLD), with its Phase II clinical trial results accepted for presentation at the 2025 annual meeting, marking a breakthrough in the field [1] Company Summary - Guangshentang's subsidiary, Fujian Guangshenzhonglin Biotechnology Co., Ltd., has achieved a milestone with its drug GST-HG131, which is the first oral HBsAg inhibitor to complete Phase II clinical trials globally [1] - The drug is noted for its good accessibility and patient compliance, indicating potential for widespread use in hepatitis B treatment [1]

Core Insights - Guangshengtang's innovative drug GST-HG131 has received significant recognition from the American Association for the Study of Liver Diseases (AASLD), with its Phase II clinical trial results accepted for presentation at The Liver Meeting® 2025 [1][2] Group 1: Clinical Trial Results - GST-HG131 is the world's first oral HBsAg inhibitor to complete Phase II clinical trials, demonstrating good accessibility and patient compliance [2] - In the Phase II trial, HBsAg levels decreased rapidly, with the fastest patient showing a reduction of approximately 0.8 Log10 IU/mL within 7 days; the third group (30mg, BID, three-month treatment) achieved an average reduction to 12.88%, representing an 87.12% decrease [2] - 76.5% of patients in the third group reached HBsAg levels ≤100 IU/mL, a key indicator of partial cure, with sustained reductions observed even after treatment cessation [2] Group 2: Mechanism and Future Prospects - GST-HG131 exhibits significant suppression of HBsAg, while GST-HG141 further inhibits HBV DNA and has potential effects on HBV cccDNA, preventing viral rebound [3] - The combination of GST-HG131 and GST-HG141 in a Phase II clinical trial for previously treated hepatitis B patients is expected to challenge clinical cure outcomes, supported by national policies for innovative drug development [3]